The first photosensitizer (PS) with long wavelength absorption near 800 nm and fluorescence above 830 nm for fluorescence-guided surgery and PDT of brain cancer.
• Photobac-PDT has received Orphan Drug Designation for the treatment of glioblastoma (brain cancer) from the United States FDA
• Approved IND of Photobac-PDT by the US FDA for Phase I clinical trials of glioblastoma (brain cancer) at Roswell Park Comprehensive Cancer Center, Buffalo, NY.
• Due to its long wavelength absorption near 800 nm, the tumor cells present in margin and/or infiltrating cells deeply seated after fluorescence-guided surgery will also be destroyed after NIR PDT (longer the wavelength, deeper the tissue penetration).
• In contrast to various porphyrin-based photosenitizers, Photobac shows limited skin phototoxicity.
An efficient nuclear Positron Emission Tomography (PET) imaging agent
After a successful pre-IND with FDA, the IND is under submission and later a Phase I Clinical trial will be engaged.
Advantages of PET-ONCO ( I-124 analog):
• Can be used for imaging a variety of tumors and metastases.
• In contrast to F-18 FDG-PET, PET-ONCO can be used for imaging bladder, kidney, brain, pancreatic cancers.
• Need ¼ of F-18 FDG dose for imaging tumors (from mice model studies)
• Half-life: 4.2 days
• For the production of PET imaging agent, cyclotrons are not required near the imaging facilities, which will make PET-imaging more economical.
• Longer distance transportation is not an issue.
Photolitec has developed a portfolio of new nanoparticles capable of being used as a targeted drug delivery system.
Our nanoparticles are capable of carrying post-loaded imaging and chemotherapy agents
Photo-triggered release of tumor-Imaging and therapy agents (PDT and chemo-therapy) from lyophilized multi-functional NPS.